Whitepaper

Eliminate Problematic Polymorphs

Eliminate Problematic Polymorphs and Fast-Track Stable Solid Forms With X-Ray Powder Diffraction

Small molecule drugs have formed most pharmaceutical discoveries for over a century, however, approximately 40% of current active pharmaceutical ingredients (APIs) are poorly soluble, along with around 90% of drugs in development.

When working with poorly soluble and often poorly permeable molecules, it is essential to carry out thorough solid form analysis to discover and properly characterize all crystalline and amorphous forms, as well as any solvates, salts and cocrystals. In this way, substances with better bioavailability can be identified.

Download this whitepaper to learn how X-ray powder diffraction can help you:

  • Select APIs with enhanced bioavailability and stability
  • Identify and exclude polymorphs that may reduce a drug’s efficacy or safety
  • Ensure that all relevant polymorphs are included in the patent

Download this whitepaper to learn how X-ray powder diffraction can help you:

  • Select APIs with enhanced bioavailability and stability
  • Identify and exclude polymorphs that may reduce a drug’s efficacy or safety
  • Ensure that all relevant polymorphs are included in the patent

Download this Whitepaper for FREE Now!

I agree to share the above information with Malvern Panalytical and understand that I may receive materials and communications from Malvern Panalytical about their products and services.
Information you provide will be shared with the sponsors for this content. Technology Networks or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.